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     Prostaglandins (PGs) and related compounds are called "local hormones" that are synthesized from 
polyunsaturated fatty acids including arachidonic acid as a major essential fatty acid, and provide specific 
effects on target cells close to their site of the biosynthesis. Almost all the mammalian cells except red 
blood cells produce prostaglandins and their related compounds such as prostacyclins, thromboxane, 
leukotrienes and other bioactive lipids that are collectively known as eicosanoids. Biosynthesis of 
prostaglandins through the cyclooxygenase (COX) pathway involves oxidation and subsequent 
isomerization of membrane-derived free arachidonic acid via three sequential enzymatic reactions. The 
process is initiated through the release of arachidonic acid from membrane phospholipids, a reaction 
catalysed by phospholipases A2 that catalyzes the hydrolysis of arachidonic acid from sn-2 position of 
phospholipids. The released arachidonic acid is then subsequently metabolized to prostaglandin H2 by the 
action of COX enzymes. There are two isoforms of COX. Of these, COX-1 is constitutively expressed in 
most of the cells and is mainly utilized in the immediate prostaglandin biosynthesis important for 
homeostasis and certain physiological functions. On the other hand, COX-2 is expressed inducibly and is 
utilized for delayed prostaglandin biosynthesis. The final step for the biosynthesis of prostaglandin is the 
conversion of prostaglandin H2 to various bioactive derivatives such as PGD2, PGE2, PGF2α, and PGI2 by 
their specific terminal synthases, such as PGD synthase (PGDS), PGE synthase, PGF synthase, and PGI 
synthase respectively. The J2 series of PGs including PGJ2, 15-deoxy-Δ12,14-PGJ2 and Δ12-PGJ2 are 
generated non-enzymatically from PGD2 through the dehydration and isomerization. Alternatively, PGD2 
can be enzymatically converted to 11β-PGF2α by the action of enzyme PGD 11-keto-reductase in some 
tissues. Among the prostaglandins, PGE2 and PGF2α have been shown to serve as anti-adipogenic 
prostanoids that exert their effects through the binding to the specific cell-surface receptors of EP 
receptors and FP receptor. Nevertheless, it remains still unclear regarding the role of these endogenous 
prostanoids synthesized by preadipocytes only during the growth phase in adipogenesis program leading 
to the differentiation and maturation of adipocytes. On the other hand, peroxisome proliferator-activated 
receptor γ (PPARγ), a member of nuclear hormone receptor and a ligand-dependent transcription factor, is 
a master regulator of adipocyte differentiation. The PGJ2 derivatives are effective to be active ligands for 
PPARγ and to stimulate adipogenesis during the differentiation and maturation of cultured adipocytes. 
Cultured 3T3-L1 cells have been shown to express specifically lipocalin-type PGD synthase (L-PGDS) 
during the progress of adipogenesis associated with co-expression of PPARγ. However, the role of 
intracellular L-PGDS is still complicated because PGD2 and the related metabolites or derivatives exert 
other different effects on the function of adipocytes. For example, 9α,11β-PGF2α, an enzymatic degraded 
product of PGD2, acts as an anti-adipogenic factor in cultured adipocytes. In addition, 15d-PGJ2 has been 
implicated in the inhibition of inflammatory response associated with inducible synthesis of COX-2. 
Moreover, PGD2 also acts through the cell-surface receptors with different subtypes such as DP1 and 
CRTH2 receptors. Interestingly, active form of L-PGDS has been shown to inhibit the phosphorylation of 
Akt, a serie/threonine kinase. The phosphorylated Akt has been previously implicated in spontaneous 
differentiation into adipocytes in a PG-independent manner. Thus, the functions of intracellular L-PGDS 
in adipocytes at different life stages still remain to be determined. Additionally, the effect of LPGDS 
product on the biosynthesis of other prostanoids in the adipocytes remains to be obscure.  
     Initially, I have focused the enhanced biosynthesis of PGE2 and PGF2α during the growth phase 
upon stimulation with a mixture of phorbol 12-myristate 13-acetate, a mitogenic factor, and calcium 
ionophore A23187. Here, I studied the interactive effect of 15d-PGJ2 on the inducible synthesis of the 
endogenous prostaglandins in cultured preadipocytes and its implication in adipogenesis program. 
15d-PGJ2 interfered significantly the endogenous synthesis of those PGE2 and PGF2α in response to cell 
stimuli by suppressing the induction of COX-2 at both mRNA and protein level. In contrast, Δ12-PGJ2 and 
troglitazone, a PPARγ agonist, had almost no inhibitory effects, indicating a mechanism independent of 
the activation of peroxisome proliferator-activated receptor-γ for the action of 15-PGJ2. 
Pyrrolidinedithiocarbamate (PDTC), an NF-κB inhibitor, effectively inhibited on the inducible synthesis 
of those both PGE2 and PGF2α in preadipocytes. To explore the molecular mechanism behind the reduced 
expression of COX-2, we have checked the activation of nuclear receptor NF-κB and degradation of 
IκB-α in presence or absence of 15d-PGJ2 and PDTC under the stimulatory condition with a mixture of 
PMA and A23187. The stimulated nuclear translocation of NF-κB by PMA was significantly inhibited by 
both 15d-PGJ2 and PDTC, which effects were further confirmed by the increase in the cytosolic levels of 
NF-κB. Moreover, 15d-PGJ2 and PDTC were individually sufficient to inhibit the degradation of IκB-α, 
an inhibitory protein for NF-κB. Taken together, the findings indicate that 15d-PGJ2 inhibits degradation 
of IκB-α as well as activation of NF-κB, resulting in the reduced expression of COX-2. Endogenous PGs 
generated by preadipocytes only during the growth phase in response to the cell stimuli autonomously 
attenuated the subsequent adipogenesis program leading to the differentiation and maturation of 
adipocytes. These effects were prevented by additional co-incubation of preadipocytes with either 
15d-PGJ2 or PDTC although 15d-PGJ2 alone has no stimulatory effect. Moreover, while treating the cells 
with PGE2 and PGF2α, 15d-PGJ2 was unable to block the inhibitory effects of these anti-adipogenic PGs 
on the adipogenesis program in preadipocytes. The results suggest that 15d-PGJ2 interferes at the 
biosynthetic pathway of those anti-adipogenic PGs but not at their receptors or subsequent pathways 
through which PGE2 and PGF2α provide anti-adipogenic actions. In short, the findings suggest that 
15d-PGJ2 inhibits the biosynthesis of PGE2 and PGF2α by inhibiting the activation of NF-κB followed by 
reduced expression of COX-2. This effect of 15d-PGJ2 contributes to the up-regulation of adipogenesis 
during the maturation phase. 
     15d-PGJ2 and Δ12-PGJ2 are nonenzymatic degraded product of PGD2 which is formed by the action 
of terminal synthase enzyme called lipcalin-type prostaglandin D synthase. To evaluate the role of 
L-PGDS in cultured adipocytes and the precursor cells, I attempted to interfere the intracellular 
expression of L-PGDS in cultured 3T3-L1 preadipocytes by stable transfection with a mammalian 
expression vector having the full-length complementary DNA of L-PGDS oriented in the antisense 
direction. The neomycin-resistant gene in the vector was expressed in the cloned transfectants with the 
vector only or that with antisense L-PGDS, whereas it was not detectable in untransfected parent cells. As 
expected, the stable transfection of L-PGDS oriented in the antisense direction significantly suppressed 
the transcript levels and the protein levels of L-PGDS in the cloned transfectants. The cloned transfectants 
with antisense L-PGDS also exhibited the reduced biosynthesis of PGD2 and the formation of its 
dehydration product of Δ12-PGJ2 from exogenous and endogenous arachidonic acid. By contrast, the 
synthesis of PGE2 was not influenced appreciably, indicating that there were no interfering effects on 
cyclooxygenases and PGE synthases. The stable transfection of antisense L-PGDS induced markedly the 
stimulation of fat storage in cultured adipocytes compared to the wild type cells during the maturation 
phase. In addition, the spontaneous accumulation of fats occurred in the transfectants with antisense 
L-PGDS without undergoing the stimulation with inducing factors. Moreover, the transfectants with 
antisense L-PGDS expressed aP2, leptin, and GLUT-4 as typical adipogenesis markers at higher levels 
than other control cells although the expression levels of PPARγ, LPL, and adiponectin remained 
unchanged, indicating the up-regulation of adipogenesis program. The stimulated adipogenesis was 
significantly reversed by exogenous anti-adipogenic prostanoids such as PGE2 and PGF2α, while the 
storage of fats was additionally enhanced by exogenous pro-adipogenic 15d-PGJ2. These results suggest 
that the stably reduced expression levels of L-PGDS regulates positively adipogenesis program in a 
cellular mechanism independent of pro-adipogenic action of PGJ2 series.  
